Show simple item record

dc.contributor.authorKisby, Thomas; orcid: 0000-0002-8432-7910
dc.contributor.authorYilmazer, Açelya; orcid: 0000-0003-2712-7450
dc.contributor.authorKostarelos, Kostas; orcid: 0000-0002-2224-6672; email: kostas.kostarelos@manchester.ac.uk
dc.date.accessioned2021-08-26T00:54:32Z
dc.date.available2021-08-26T00:54:32Z
dc.date.issued2021-08
dc.identifierpubmed: 34381200
dc.identifierdoi: 10.1038/s41565-021-00946-9
dc.identifierpii: 10.1038/s41565-021-00946-9
dc.identifier.citationNature nanotechnology, volume 16, issue 8, page 843-850
dc.identifier.urihttp://hdl.handle.net/10034/625690
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionPublication status: ppublish
dc.languageeng
dc.sourceeissn: 1748-3395
dc.titleReasons for success and lessons learnt from nanoscale vaccines against COVID-19.
dc.typearticle
dc.date.updated2021-08-26T00:54:32Z


This item appears in the following Collection(s)

Show simple item record